Human eyes may develop various serious pathologies, especially with age. Many of those pathologies have been connected to oxidative stress involving mitochondria. Due to highly targeted delivery of SkQ1 to mitochondria and its potency as antioxidant, topical application of SkQ1-based formulations proved to be very effective in treating several eye pathologies in animal models and in humans. More than a dozen studies have been conducted and showed SkQ1 effectiveness in such critical therapeutic areas as

  • Age-related macular degeneration (AMD),
  • Dry eye syndrome (DES),
  • Non-infectious uveitis,
  • Cataract.

Formal clinical trials covering several ophthalmic indications are underway in Russia and the U.S. For our up-to-date clinical trial schedule please visit mitotechpharma.com.